메뉴 건너뛰기




Volumn 29, Issue 12, 2015, Pages 1221-1230

Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients

Author keywords

Atomoxetine; attention deficit hyperactivity disorder; clinical outcome; efficacy; maintenance; norepinephrine transporter blockade; pharmacology; responder rate; response; review

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; NORADRENALIN TRANSPORTER; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT;

EID: 84948691634     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115602489     Document Type: Review
Times cited : (50)

References (86)
  • 1
    • 62649135353 scopus 로고    scopus 로고
    • Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial
    • Adler LA, Spencer T, Brown TE, et al. (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial. J Clin Psychopharmacol 29: 44-50.
    • (2009) J Clin Psychopharmacol , vol.29 , pp. 44-50
    • Adler, L.A.1    Spencer, T.2    Brown, T.E.3
  • 2
    • 84948666395 scopus 로고    scopus 로고
    • All Wales Therapeutics and Toxicology Centre. Cardiff: All Wales Therapeutics and Toxicology Centre, United Kingdom. AWMSG (All Wales Medicine Strategy Group) Secretariat Assessment Report Number 1361: 1-18. Available at: (accessed 1 June 2015)
    • All Wales Therapeutics and Toxicology Centre (2014) Atomoxetine. Cardiff: All Wales Therapeutics and Toxicology Centre, United Kingdom. AWMSG (All Wales Medicine Strategy Group) Secretariat Assessment Report Number 1361: 1-18. Available at: www.awmsg.org/awmsgonline/app/appraisalinfo/1361 (. accessed 1 June 2015).
    • (2014) Atomoxetine
  • 3
    • 0003472502 scopus 로고    scopus 로고
    • American Psychiatric Association. Arlington, VA: American Psychiatric Publishing
    • American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Publishing.
    • (2013) Diagnostic and Statistical Manual of Mental Disorders
  • 4
    • 19944431059 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder
    • Arnold LE, Lindsay RL, Conners CK, et al. (2004) A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14: 542-554.
    • (2004) J Child Adolesc Psychopharmacol , vol.14 , pp. 542-554
    • Arnold, L.E.1    Lindsay, R.L.2    Conners, C.K.3
  • 5
    • 79958143939 scopus 로고    scopus 로고
    • Catecholamine influences on dorsolateral prefrontal cortical networks
    • Arnsten AFT, (2011) Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 69: e89-99.
    • (2011) Biol Psychiatry , vol.69 , pp. e89-99
    • Arnsten, A.F.T.1
  • 6
    • 84859108120 scopus 로고    scopus 로고
    • Neurobiological circuits regulating attention, cognitive control, motivation and emotion: Disruptions in neurodevelopmental psychiatric disorders
    • Arnsten AFT, Rubia K, (2012) Neurobiological circuits regulating attention, cognitive control, motivation and emotion: Disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry 51: 356-367.
    • (2012) J Am Acad Child Adolesc Psychiatry , vol.51 , pp. 356-367
    • Arnsten, A.F.T.1    Rubia, K.2
  • 7
    • 84906058265 scopus 로고    scopus 로고
    • Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials
    • Asherson P, Bushe C, Saylor K, et al. (2014) Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 28: 837-846.
    • (2014) J Psychopharmacol , vol.28 , pp. 837-846
    • Asherson, P.1    Bushe, C.2    Saylor, K.3
  • 9
    • 13844308072 scopus 로고    scopus 로고
    • Biomarkers in psychotropic drug development: Integration of data across multiple domains
    • Bieck PR, Potter WZ, (2005) Biomarkers in psychotropic drug development: Integration of data across multiple domains. Annu Rev Pharmacol Toxicol 45: 227-246.
    • (2005) Annu Rev Pharmacol Toxicol , vol.45 , pp. 227-246
    • Bieck, P.R.1    Potter, W.Z.2
  • 10
    • 68949151924 scopus 로고    scopus 로고
    • Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: Comparison of morning and evening dosing
    • Block SL, Kelsey D, Coury D, et al. (2009) Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: Comparison of morning and evening dosing. Clin Pediatr 48: 723-733.
    • (2009) Clin Pediatr , vol.48 , pp. 723-733
    • Block, S.L.1    Kelsey, D.2    Coury, D.3
  • 11
    • 77955100309 scopus 로고    scopus 로고
    • Post hoc analysis: Early changes in ADHD-RS items predict longer-term response to atomoxetine in pediatric patients
    • Block SL, Williams D, Donnelly CL, et al. (2010) Post hoc analysis: Early changes in ADHD-RS items predict longer-term response to atomoxetine in pediatric patients. Clin Pediatr 49: 768-776.
    • (2010) Clin Pediatr , vol.49 , pp. 768-776
    • Block, S.L.1    Williams, D.2    Donnelly, C.L.3
  • 12
    • 84903795024 scopus 로고    scopus 로고
    • Report for the National Center for Health Statistics. Vital Health Stat 10 (258). Washington, DC. U.S. Department of Health and Human Services. Available at: (accessed 1 June 2015)
    • Bloom B, Jones LI, Freeman G, (2013) Summary Health Statistics for U.S. Children: National Health Interview Survey, 2012. Report for the National Center for Health Statistics. Vital Health Stat 10 (258). Washington, DC.: U.S. Department of Health and Human Services. Available at: www.cdc.gov/nchs/data/series/sr-10/sr10-258.pdf (. accessed 1 June 2015).
    • (2013) Summary Health Statistics for U.S. Children: National Health Interview Survey, 2012
    • Bloom, B.1    Jones, L.I.2    Freeman, G.3
  • 13
    • 56149084870 scopus 로고    scopus 로고
    • Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder
    • Brams M, Mao AR, Doyle RL, (2008) Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad Med 120: 69-88.
    • (2008) Postgrad Med , vol.120 , pp. 69-88
    • Brams, M.1    Mao, A.R.2    Doyle, R.L.3
  • 14
    • 84864410374 scopus 로고    scopus 로고
    • Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: Randomized withdrawal design
    • Brams M, Weisler R, Findling RL, et al. (2012) Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: Randomized withdrawal design. J Clin Psychiatry 73: 977-983.
    • (2012) J Clin Psychiatry , vol.73 , pp. 977-983
    • Brams, M.1    Weisler, R.2    Findling, R.L.3
  • 15
    • 33847282861 scopus 로고    scopus 로고
    • A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year
    • Buitelaar JK, Michelson D, Danckaerts M, et al. (2007) A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 61: 694-699.
    • (2007) Biol Psychiatry , vol.61 , pp. 694-699
    • Buitelaar, J.K.1    Michelson, D.2    Danckaerts, M.3
  • 16
    • 84879506883 scopus 로고    scopus 로고
    • Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians
    • Bushe CJ, Savill N, (2011) Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians. J Central Nervous System Dis 3: 209-217.
    • (2011) J Central Nervous System Dis , vol.3 , pp. 209-217
    • Bushe, C.J.1    Savill, N.2
  • 17
    • 84895550603 scopus 로고    scopus 로고
    • Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: Focus on clinical efficacy and safety
    • Bushe CJ, Savill N, (2014) Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: Focus on clinical efficacy and safety. J Psychopharmacol 28: 204-211.
    • (2014) J Psychopharmacol , vol.28 , pp. 204-211
    • Bushe, C.J.1    Savill, N.2
  • 18
    • 84863554395 scopus 로고    scopus 로고
    • Weight change from 3-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database
    • Bushe CJ, Slooff CJ, Haddad PM, et al. (2012) Weight change from 3-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry 73: e749-755.
    • (2012) J Clin Psychiatry , vol.73 , pp. e749-755
    • Bushe, C.J.1    Slooff, C.J.2    Haddad, P.M.3
  • 19
    • 0036848458 scopus 로고    scopus 로고
    • Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder
    • Bymaster FP, Katner JS, Nelson DL, et al. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacol 27: 699-711.
    • (2002) Neuropsychopharmacol , vol.27 , pp. 699-711
    • Bymaster, F.P.1    Katner, J.S.2    Nelson, D.L.3
  • 20
    • 80052049128 scopus 로고    scopus 로고
    • Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
    • Castells X, Ramos-Quiroga JA, Bosch R, et al. (2011) Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 15: CD007813.
    • (2011) Cochrane Database Syst Rev , vol.15 , pp. CD007813
    • Castells, X.1    Ramos-Quiroga, J.A.2    Bosch, R.3
  • 21
    • 84896775749 scopus 로고    scopus 로고
    • Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication. A population-based study
    • Chang Z, Lichtenstein P, D'Onofrio BM, et al. (2014) Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication. A population-based study. JAMA Psychiatry 71: 319-325.
    • (2014) JAMA Psychiatry , vol.71 , pp. 319-325
    • Chang, Z.1    Lichtenstein, P.2    D'Onofrio, B.M.3
  • 22
    • 84921871231 scopus 로고    scopus 로고
    • Suboptimal dosing of Strattera (atomoxetine) for ADHD patients
    • Clemow DB, (2014) Suboptimal dosing of Strattera (atomoxetine) for ADHD patients. Postgrad Med 126: 196-198.
    • (2014) Postgrad Med , vol.126 , pp. 196-198
    • Clemow, D.B.1
  • 23
    • 84921719451 scopus 로고    scopus 로고
    • The potential for misuse and abuse of medications in ADHD: A review
    • Clemow DB, Walker DJ, (2014) The potential for misuse and abuse of medications in ADHD: A review. Postgrad Med 126: 64-81.
    • (2014) Postgrad Med , vol.126 , pp. 64-81
    • Clemow, D.B.1    Walker, D.J.2
  • 24
    • 84901198640 scopus 로고    scopus 로고
    • Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: Randomized-withdrawal study design
    • Coghill DR, Banaschewski T, Lecendreux M, et al. (2014) Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: Randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry 53: 647-657.
    • (2014) J Am Acad Child Adolesc Psychiatry , vol.53 , pp. 647-657
    • Coghill, D.R.1    Banaschewski, T.2    Lecendreux, M.3
  • 25
    • 84882631139 scopus 로고    scopus 로고
    • Atomoxetine for attention deficit hyperactivity disorder in the adulthood: A meta-analysis and meta-regression
    • Cunill R, Castells X, Tobias A, et al. (2013) Atomoxetine for attention deficit hyperactivity disorder in the adulthood: A meta-analysis and meta-regression. Pharmacoepi Drug Saf 22: 961-969.
    • (2013) Pharmacoepi Drug Saf , vol.22 , pp. 961-969
    • Cunill, R.1    Castells, X.2    Tobias, A.3
  • 26
    • 62849109902 scopus 로고    scopus 로고
    • Review of ADHD pharmacotherapies: Advantages, disadvantages and clinical pearls
    • Daughton JM, Kratochvil CJ, (2009) Review of ADHD pharmacotherapies: Advantages, disadvantages and clinical pearls. J Am Acad Child Adolesc Psychiatry 48: 240-248.
    • (2009) J Am Acad Child Adolesc Psychiatry , vol.48 , pp. 240-248
    • Daughton, J.M.1    Kratochvil, C.J.2
  • 27
    • 79958115602 scopus 로고    scopus 로고
    • The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder
    • Del Campo N, Chamberlain SR, Sahakian BJ, et al. (2011) The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 69: e145-57.
    • (2011) Biol Psychiatry , vol.69 , pp. e145-e157
    • Del Campo, N.1    Chamberlain, S.R.2    Sahakian, B.J.3
  • 28
    • 79955783537 scopus 로고    scopus 로고
    • Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: Analysis of Canadian open-label studies
    • Dickson RA, Maki E, Gibbins C, et al. (2011) Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: Analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health 5: 14.
    • (2011) Child Adolesc Psychiatry Ment Health , vol.5 , pp. 14
    • Dickson, R.A.1    Maki, E.2    Gibbins, C.3
  • 29
    • 84873096668 scopus 로고    scopus 로고
    • Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: A randomized, double-blind, placebo-controlled trial
    • Durell TM, Adler LA, Williams DW, et al. (2013) Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: A randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 33: 45-54.
    • (2013) J Clin Psychopharmacol , vol.33 , pp. 45-54
    • Durell, T.M.1    Adler, L.A.2    Williams, D.W.3
  • 30
    • 4143144205 scopus 로고    scopus 로고
    • Catecholamine metabolism: A contemporary view with implications for physiology and medicine
    • Eisenhofer G, Kopin IJ, Goldstein DS, (2004) Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacol Rev 56: 331-349.
    • (2004) Pharmacol Rev , vol.56 , pp. 331-349
    • Eisenhofer, G.1    Kopin, I.J.2    Goldstein, D.S.3
  • 32
    • 76249085587 scopus 로고    scopus 로고
    • Using meta-analysis to compare the efficacy of medications for attention-deficit/ hyperactivity disorder in youths
    • Faraone SV, (2009) Using meta-analysis to compare the efficacy of medications for attention-deficit/ hyperactivity disorder in youths. P T 34: 678-694.
    • (2009) P T , vol.34 , pp. 678-694
    • Faraone, S.V.1
  • 33
    • 84855986810 scopus 로고    scopus 로고
    • Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults
    • Faraone SV, (2012) Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Attention Disord 16: 128-137.
    • (2012) J Attention Disord , vol.16 , pp. 128-137
    • Faraone, S.V.1
  • 34
    • 34248151557 scopus 로고    scopus 로고
    • Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder
    • Fayyad J, De Graaf R, Kessler R, et al. (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190: 402-409.
    • (2007) Br J Psychiatry , vol.190 , pp. 402-409
    • Fayyad, J.1    De Graaf, R.2    Kessler, R.3
  • 35
    • 84930867980 scopus 로고    scopus 로고
    • Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis
    • Fridman M, Hodgkins PS, Kahle JS, et al. (2015) Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis. EU Psychiatry 30: 521-527.
    • (2015) EU Psychiatry , vol.30 , pp. 521-527
    • Fridman, M.1    Hodgkins, P.S.2    Kahle, J.S.3
  • 36
    • 84907339660 scopus 로고    scopus 로고
    • Adherence, persistence and medication discontinuation in patients with attention-deficit/hyperactivity disorder: A systematic literature review
    • Gajria K, Lu M, Sikirica V, et al. (2014) Adherence, persistence and medication discontinuation in patients with attention-deficit/hyperactivity disorder: A systematic literature review. Neuropsychiatric Dis Treat 10: 1543-1569.
    • (2014) Neuropsychiatric Dis Treat , vol.10 , pp. 1543-1569
    • Gajria, K.1    Lu, M.2    Sikirica, V.3
  • 38
    • 0031798071 scopus 로고    scopus 로고
    • Pharmacotherapy of adolescent attention deficit hyperactivity disorder: Challenges, choices and caveats
    • Garland EJ, (1998) Pharmacotherapy of adolescent attention deficit hyperactivity disorder: Challenges, choices and caveats. J Psychopharmacol 12: 385-395.
    • (1998) J Psychopharmacol , vol.12 , pp. 385-395
    • Garland, E.J.1
  • 39
    • 65949112261 scopus 로고    scopus 로고
    • Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents
    • Garnock-Jones KP, Keating GM, (2009) Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatr Drugs 11: 203-226.
    • (2009) Pediatr Drugs , vol.11 , pp. 203-226
    • Garnock-Jones, K.P.1    Keating, G.M.2
  • 40
    • 34548084838 scopus 로고    scopus 로고
    • Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder
    • Geller D, Donnelly C, Lopez F, et al. (2007) Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 46: 1119-1127.
    • (2007) J Am Acad Child Adolesc Psychiatry , vol.46 , pp. 1119-1127
    • Geller, D.1    Donnelly, C.2    Lopez, F.3
  • 41
    • 85008668690 scopus 로고    scopus 로고
    • Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: A multinational 10-week randomized double-blind placebo-controlled Asian study
    • [Epub ahead of print] 7 November 2013. DOI: 10.1177/1087054713510352
    • Goto T, Hirata Y, Takita Y, et al. (2013) Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: A multinational 10-week randomized double-blind placebo-controlled Asian study. J Atten Dis. [Epub ahead of print] 7 November 2013. DOI: 10.1177/1087054713510352.
    • (2013) J Atten Dis
    • Goto, T.1    Hirata, Y.2    Takita, Y.3
  • 42
    • 70449718852 scopus 로고    scopus 로고
    • Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review
    • Hammerness P, McCarthy K, Mancuso E, et al. (2009) Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A review. Neuropsychiat Dis Treat 5: 215-226.
    • (2009) Neuropsychiat Dis Treat , vol.5 , pp. 215-226
    • Hammerness, P.1    McCarthy, K.2    Mancuso, E.3
  • 43
    • 84876695871 scopus 로고    scopus 로고
    • Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: An open-label extension study
    • Harfterkamp M, Buitelaar JK, Minderaa RB, et al. (2013) Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: An open-label extension study. J Child Adolesc Pscyhopharmacol 23: 1-6.
    • (2013) J Child Adolesc Pscyhopharmacol , vol.23 , pp. 1-6
    • Harfterkamp, M.1    Buitelaar, J.K.2    Minderaa, R.B.3
  • 44
    • 82455186436 scopus 로고    scopus 로고
    • Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis
    • Hazell PL, Kohn MR, Dickson R, et al. (2011) Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis. J Atten Disord 15: 674-683.
    • (2011) J Atten Disord , vol.15 , pp. 674-683
    • Hazell, P.L.1    Kohn, M.R.2    Dickson, R.3
  • 45
    • 84929938812 scopus 로고    scopus 로고
    • Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder
    • Hirata Y, Goto T, Takita Y, et al. (2014) Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Asia Pac Psychiatry 6: 292-301.
    • (2014) Asia Pac Psychiatry , vol.6 , pp. 292-301
    • Hirata, Y.1    Goto, T.2    Takita, Y.3
  • 46
    • 84932183602 scopus 로고    scopus 로고
    • A review of OROS methylphenidate (Concerta®) in the treatment of attention-deficit/hyperactivity disorder
    • Katzman MA, Sternat T, (2014) A review of OROS methylphenidate (Concerta®) in the treatment of attention-deficit/hyperactivity disorder. CNS Drugs 28: 1005-1033.
    • (2014) CNS Drugs , vol.28 , pp. 1005-1033
    • Katzman, M.A.1    Sternat, T.2
  • 47
    • 4644226347 scopus 로고    scopus 로고
    • Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial
    • Kelsey DK, Sumner CR, Casat CD, et al. (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114: e1-8.
    • (2004) Pediatrics , vol.114 , pp. e1-8
    • Kelsey, D.K.1    Sumner, C.R.2    Casat, C.D.3
  • 48
    • 20444422495 scopus 로고    scopus 로고
    • Patterns and predictors of ADHD persistence into adulthood: Results from the National Comorbidity Survey Replication
    • Kessler RC, Adler LA, Barkley R, et al. (2005) Patterns and predictors of ADHD persistence into adulthood: Results from the National Comorbidity Survey Replication. Biol Psychiatry 57: 1442-1451.
    • (2005) Biol Psychiatry , vol.57 , pp. 1442-1451
    • Kessler, R.C.1    Adler, L.A.2    Barkley, R.3
  • 49
    • 85035146867 scopus 로고    scopus 로고
    • The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication
    • Kessler RC, Adler L, Barkley R, et al. (2006) The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 163: 716-723.
    • (2006) Am J Psychiatry , vol.163 , pp. 716-723
    • Kessler, R.C.1    Adler, L.2    Barkley, R.3
  • 50
    • 69049093007 scopus 로고    scopus 로고
    • Limits of meta-analysis: Methylphenidate in the treatment of adult attention-deficit hyperactivity disorder
    • Koesters M, Becker T, Kilian R, et al. (2009) Limits of meta-analysis: Methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23: 733-744.
    • (2009) J Psychopharmacol , vol.23 , pp. 733-744
    • Koesters, M.1    Becker, T.2    Kilian, R.3
  • 51
    • 84948705675 scopus 로고    scopus 로고
    • Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing
    • Leibowitz M, Ereshefsky L, Lin Q, et al. (2005) Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing. Eur Neuropsychopharmacol 15: S594-595.
    • (2005) Eur Neuropsychopharmacol , vol.15 , pp. S594-595
    • Leibowitz, M.1    Ereshefsky, L.2    Lin, Q.3
  • 52
    • 84868257163 scopus 로고    scopus 로고
    • Altered gene expression in the prefrontal cortex of young rats induced by the ADHD drug atomoxetine
    • Lempp T, Toennes SW, Wunder C, et al. (2013) Altered gene expression in the prefrontal cortex of young rats induced by the ADHD drug atomoxetine. Progr Neuropsychopharmacol Biol Psychiatr 40: 221-228.
    • (2013) Progr Neuropsychopharmacol Biol Psychiatr , vol.40 , pp. 221-228
    • Lempp, T.1    Toennes, S.W.2    Wunder, C.3
  • 53
    • 84899900387 scopus 로고    scopus 로고
    • Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: A pilot project
    • Leuchter AF, McGough JJ, Korb AS, et al. (2014) Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: A pilot project. J Psychiatric Res 54: 11-18.
    • (2014) J Psychiatric Res , vol.54 , pp. 11-18
    • Leuchter, A.F.1    McGough, J.J.2    Korb, A.S.3
  • 54
    • 84869441913 scopus 로고    scopus 로고
    • Medication for attention deficit-hyperactivity disorder and criminality
    • Lichtenstein P, Halldner L, Zetterqvist J, et al. (2012) Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367: 2006-2014.
    • (2012) N Engl J Med , vol.367 , pp. 2006-2014
    • Lichtenstein, P.1    Halldner, L.2    Zetterqvist, J.3
  • 55
    • 80051947398 scopus 로고    scopus 로고
    • Long-term open-label response to atomoxetine in adult ADHD: Influence of sex, emotional dysregulation and double-blind response to atomoxetine
    • Marchant BK, Reimherr FW, Halls C, et al. (2011) Long-term open-label response to atomoxetine in adult ADHD: Influence of sex, emotional dysregulation and double-blind response to atomoxetine. Atten Deficit Hyperact Disord 3: 237-244.
    • (2011) Atten Deficit Hyperact Disord , vol.3 , pp. 237-244
    • Marchant, B.K.1    Reimherr, F.W.2    Halls, C.3
  • 56
    • 73449130156 scopus 로고    scopus 로고
    • Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: A 6-week, randomized, placebo-controlled, double-blind trial in Russia
    • Martenyi F, Zavadenko NN, Jarkova NB, et al. (2010) Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: A 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry 19: 57-66.
    • (2010) Eur Child Adolesc Psychiatry , vol.19 , pp. 57-66
    • Martenyi, F.1    Zavadenko, N.N.2    Jarkova, N.B.3
  • 57
    • 12244298956 scopus 로고    scopus 로고
    • Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies
    • Michelson D, Adler L, Spencer T, et al. (2003) Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53: 112-120.
    • (2003) Biol Psychiatry , vol.53 , pp. 112-120
    • Michelson, D.1    Adler, L.2    Spencer, T.3
  • 58
    • 0036842531 scopus 로고    scopus 로고
    • Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study
    • Michelson D, Allen AJ, Busner J, et al. (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901.
    • (2002) Am J Psychiatry , vol.159 , pp. 1896-1901
    • Michelson, D.1    Allen, A.J.2    Busner, J.3
  • 59
    • 3042559692 scopus 로고    scopus 로고
    • Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study
    • Michelson D, Buitelaar JK, Danckaerts M, et al. (2004) Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43: 896-904.
    • (2004) J Am Acad Child Adolesc Psychiatry , vol.43 , pp. 896-904
    • Michelson, D.1    Buitelaar, J.K.2    Danckaerts, M.3
  • 60
    • 0035511622 scopus 로고    scopus 로고
    • Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study
    • Michelson D, Faries D, Wernicke J, et al. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108: e83.
    • (2001) Pediatrics , vol.108 , pp. e83
    • Michelson, D.1    Faries, D.2    Wernicke, J.3
  • 61
    • 78651340717 scopus 로고    scopus 로고
    • Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine
    • Montoya A, Escobar R, García-Polavieja MJ, et al. (2011) Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. J Child Neurol 26: 31-36.
    • (2011) J Child Neurol , vol.26 , pp. 31-36
    • Montoya, A.1    Escobar, R.2    García-Polavieja, M.J.3
  • 62
    • 72549102544 scopus 로고    scopus 로고
    • Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
    • Montoya A, Hervas A, Cardo E, et al. (2009) Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 25: 2745-2754.
    • (2009) Curr Med Res Opin , vol.25 , pp. 2745-2754
    • Montoya, A.1    Hervas, A.2    Cardo, E.3
  • 63
    • 84947863345 scopus 로고    scopus 로고
    • Measurement-based care in the treatment of clinical depression
    • Morris DW, Toups M, Trivedi MH, (2012) Measurement-based care in the treatment of clinical depression. FOCUS 10: 428-433.
    • (2012) FOCUS , vol.10 , pp. 428-433
    • Morris, D.W.1    Toups, M.2    Trivedi, M.H.3
  • 64
    • 53049088671 scopus 로고    scopus 로고
    • National Institute for Health and Clinical Excellence. NICE clinical guideline 72. Last modified March 2013. London: NICE. Available at: (online article accessed 1 June 2015)
    • National Institute for Health and Clinical Excellence (2008) Attention deficit hyperactivity disorder diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. Last modified March 2013. London: NICE. Available at: www.nice.org.uk/guidance/cg72 (online article. accessed 1 June 2015).
    • (2008) Attention Deficit Hyperactivity Disorder Diagnosis and Management of ADHD in Children, Young People and Adults
  • 65
    • 44949116355 scopus 로고    scopus 로고
    • Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response
    • Newcorn JH, Kratochvil CJ, Allen AJ, et al. (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 165: 721-730.
    • (2008) Am J Psychiatry , vol.165 , pp. 721-730
    • Newcorn, J.H.1    Kratochvil, C.J.2    Allen, A.J.3
  • 66
    • 67650290119 scopus 로고    scopus 로고
    • Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: The Integrated Data Exploratory Analysis (IDEA) study
    • Newcorn JH, Sutton VK, Weiss MD, et al. (2009) Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: The Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry 48: 511-518.
    • (2009) J Am Acad Child Adolesc Psychiatry , vol.48 , pp. 511-518
    • Newcorn, J.H.1    Sutton, V.K.2    Weiss, M.D.3
  • 67
    • 85008682114 scopus 로고    scopus 로고
    • An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD
    • [Epub ahead of print] 8 2013. DOI: 10.1177/1087054713476549
    • Ni HC, Lin YJ, Gau SSF, et al. (2013a) An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord. [Epub ahead of print] 8 2013. DOI: 10.1177/1087054713476549.
    • (2013) J Atten Disord
    • Ni, H.C.1    Lin, Y.J.2    Gau, S.S.F.3
  • 68
    • 84883412659 scopus 로고    scopus 로고
    • A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder
    • Ni HC, Shang CY, Gau SSF, et al. (2013b) A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 16: 1959-1973.
    • (2013) Int J Neuropsychopharmacol , vol.16 , pp. 1959-1973
    • Ni, H.C.1    Shang, C.Y.2    Gau, S.S.F.3
  • 69
    • 37549000561 scopus 로고    scopus 로고
    • Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Clinical approaches and review of current available evidence
    • Prasad S, Steer C, (2008) Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Clinical approaches and review of current available evidence. Paediatr Drugs 10: 39-47.
    • (2008) Paediatr Drugs , vol.10 , pp. 39-47
    • Prasad, S.1    Steer, C.2
  • 70
    • 60649101658 scopus 로고    scopus 로고
    • A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder
    • Rosler M, Fischer R, Ammer R, et al. (2009) A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259: 120-129.
    • (2009) Eur Arch Psychiatry Clin Neurosci , vol.259 , pp. 120-129
    • Rosler, M.1    Fischer, R.2    Ammer, R.3
  • 71
    • 0034001134 scopus 로고    scopus 로고
    • Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency
    • Shannon JR, Flattem NL, Jordan J, et al. (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 342: 541-549.
    • (2000) N Engl J Med , vol.342 , pp. 541-549
    • Shannon, J.R.1    Flattem, N.L.2    Jordan, J.3
  • 73
    • 85038249535 scopus 로고    scopus 로고
    • Patterns of response to atomoxetine for the treatment of adult patients with attention deficit hyperactivity disorder
    • (Supp 1)
    • Sobanski E, Leppämäki S, Bushe C, et al. (2014) Patterns of response to atomoxetine for the treatment of adult patients with attention deficit hyperactivity disorder. Abstracts of the 22nd European Congress of Psychiatry. Eur Psychiatry 29 (Supp 1): S455.
    • (2014) Abstracts of the 22nd European Congress of Psychiatry. Eur Psychiatry , vol.29 , pp. S455
    • Sobanski, E.1    Leppämäki, S.2    Bushe, C.3
  • 74
    • 0036935774 scopus 로고    scopus 로고
    • Results from two proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
    • Spencer T, Heiligenstein JH, Biederman J, et al. (2002) Results from two proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63: 1140-1147.
    • (2002) J Clin Psychiatry , vol.63 , pp. 1140-1147
    • Spencer, T.1    Heiligenstein, J.H.2    Biederman, J.3
  • 75
    • 62549108162 scopus 로고    scopus 로고
    • Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents
    • Svanborg P, Thernlund G, Gustafsson PA, et al. (2009) Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 18: 240-249.
    • (2009) Eur Child Adolesc Psychiatry , vol.18 , pp. 240-249
    • Svanborg, P.1    Thernlund, G.2    Gustafsson, P.A.3
  • 76
    • 33646467730 scopus 로고    scopus 로고
    • Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat
    • Swanson CJ, Perry KW, Koch-Krueger S, et al. (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 50: 755-760.
    • (2006) Neuropharmacology , vol.50 , pp. 755-760
    • Swanson, C.J.1    Perry, K.W.2    Koch-Krueger, S.3
  • 77
    • 84908125142 scopus 로고    scopus 로고
    • Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan and United Arab Emirates
    • Treuer T, Feng Q, Desaiah D, et al. (2014) Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan and United Arab Emirates. Int J Clin Pract 68: 1152-1160.
    • (2014) Int J Clin Pract , vol.68 , pp. 1152-1160
    • Treuer, T.1    Feng, Q.2    Desaiah, D.3
  • 78
    • 84889652757 scopus 로고    scopus 로고
    • Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain: An in vivo study
    • Udvardi PT, Föhr KJ, Henes C, et al. (2013) Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain: An in vivo study. Drug Design Develop Therapy 7: 1433-1446.
    • (2013) Drug Design Develop Therapy , vol.7 , pp. 1433-1446
    • Udvardi, P.T.1    Föhr, K.J.2    Henes, C.3
  • 79
    • 84885770183 scopus 로고    scopus 로고
    • Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomized withdrawal study
    • Upadhyaya H, Ramos-Quiroga JA, Adler LA, et al. (2013) Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: A placebo-controlled, randomized withdrawal study. Eur J Psychiat 27: 185-205.
    • (2013) Eur J Psychiat , vol.27 , pp. 185-205
    • Upadhyaya, H.1    Ramos-Quiroga, J.A.2    Adler, L.A.3
  • 80
    • 4444224449 scopus 로고    scopus 로고
    • Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles
    • Vincent S, Bieck PR, Garland EM, et al. (2004) Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109: 3202-3207.
    • (2004) Circulation , vol.109 , pp. 3202-3207
    • Vincent, S.1    Bieck, P.R.2    Garland, E.M.3
  • 81
    • 64049096199 scopus 로고    scopus 로고
    • Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): Findings from two 24-week, open-label studies
    • Wehmeier PM, Dittmann RW, Schacht A, et al. (2009) Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): Findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health 3: 5. DOI: 10.1186/1753-2000-3-5.
    • (2009) Child Adolesc Psychiatry Ment Health , vol.3 , pp. 5
    • Wehmeier, P.M.1    Dittmann, R.W.2    Schacht, A.3
  • 82
    • 84859957028 scopus 로고    scopus 로고
    • 3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder
    • 3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 26: 421-434.
    • (2012) CNS Drugs , vol.26 , pp. 421-434
    • Weisler, R.H.1    Pandina, G.J.2    Daly, E.J.3
  • 83
    • 21044444747 scopus 로고    scopus 로고
    • A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD
    • Weiss M, Tannock R, Kratochvil C, et al. (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44: 647-655.
    • (2005) J Am Acad Child Adolesc Psychiatry , vol.44 , pp. 647-655
    • Weiss, M.1    Tannock, R.2    Kratochvil, C.3
  • 84
    • 9144256611 scopus 로고    scopus 로고
    • Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment
    • Wernicke JF, Adler L, Spencer T, et al. (2004) Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment. J Clin Psychopharmacol 24: 30-35.
    • (2004) J Clin Psychopharmacol , vol.24 , pp. 30-35
    • Wernicke, J.F.1    Adler, L.2    Spencer, T.3
  • 85
    • 84921021519 scopus 로고    scopus 로고
    • Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: Treatment with atomoxetine
    • Wietecha LA, Wang S, Saylor KE, et al. (2015). Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: Treatment with atomoxetine. Clin Pediatr (Phila) 54: 164-173.
    • (2015) Clin Pediatr (Phila) , vol.54 , pp. 164-173
    • Wietecha, L.A.1    Wang, S.2    Saylor, K.E.3
  • 86
    • 79959807586 scopus 로고    scopus 로고
    • Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: A 24-week, randomized, double-blind, placebo controlled trial
    • Young JL, Sarkis E, Qiao M, et al. (2011) Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: A 24-week, randomized, double-blind, placebo controlled trial. Clin Neuropharmacol 34: 51-60.
    • (2011) Clin Neuropharmacol , vol.34 , pp. 51-60
    • Young, J.L.1    Sarkis, E.2    Qiao, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.